Cargando…
Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are immunomodulatory molecules over-expressed in lymphomas and are promising immunotherapy targets for hematologic malignancies. However, studies of PD-1/PD-L1 overexpression and their clinical significance in aggressive pedia...
Autores principales: | Fisher, Kevin E., Ferguson, Lizmery S., Coffey, Amy M., Merritt, Brian Y., Curry, Jonathan L., Marcogliese, Andrea N., Major, Angela M., Kamdar, Kala Y., Lopez-Terrada, Dolores H., Curry, Choladda V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335100/ https://www.ncbi.nlm.nih.gov/pubmed/35081690 http://dx.doi.org/10.3324/haematol.2021.280342 |
Ejemplares similares
-
Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma
por: Kameda, Takuro, et al.
Publicado: (2023) -
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
por: Leivonen, Suvi-Katri, et al.
Publicado: (2023) -
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
por: Isaev, Keren, et al.
Publicado: (2022) -
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021) -
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
por: Barraclough, Allison, et al.
Publicado: (2023)